Minerva Neurosciences (NERV) vs Tiziana Life Sciences (TLSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Minerva Neurosciences (NERV) has outperformed Tiziana Life Sciences (TLSA) over the past year, gaining 50.0% versus a loss of 49.3%. Over five years, TLSA leads with a -27.2% price change compared with -69.7% for NERV. Minerva Neurosciences is the larger company by market cap ($156.1 million vs $143.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NERV | TLSA |
|---|---|---|
| Share price | $3.27 | $1.13 |
| Market cap | $156.13M | $143.17M |
| 1-day change | 0.00% | +2.26% |
| YTD return | -18.66% | -26.17% |
| 1-year return | +50.00% | -49.31% |
| 5-year return | -69.72% | -27.15% |
| EPS (TTM) | $-36.12 | $-0.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.46 | $2.30 |
| 52-week low | $2.24 | $0.76 |
| Distance from 52-week high | -73.76% | -51.09% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +215.90% | +609.33% |
| Average volume | 184.44K | 717.23K |
| Shares outstanding | 47.75M | 127.26M |
| Employees | 7 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NERV has outperformed TLSA by 99.3 percentage points over the past year.
About Minerva Neurosciences
NERV stock →Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Tiziana Life Sciences
TLSA stock →Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
NERV vs TLSA FAQ
Which is bigger, Minerva Neurosciences or Tiziana Life Sciences?
Minerva Neurosciences (NERV) is larger, with a market capitalization of $156.13M compared with $143.17M for Tiziana Life Sciences (TLSA).
Which stock has performed better over the past year, NERV or TLSA?
NERV returned +50.00% over the past 12 months, compared with -49.31% for TLSA (price return, excluding dividends). Past performance does not predict future results.
Are Minerva Neurosciences and Tiziana Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.